表紙
市場調查報告書

市場焦點:膽道癌症

Market Spotlight: Biliary Tract Cancer

出版商 Datamonitor Healthcare 商品編碼 603949
出版日期 內容資訊 英文 46 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
市場焦點:膽道癌症 Market Spotlight: Biliary Tract Cancer
出版日期: 2019年12月31日內容資訊: 英文 46 Pages
簡介

本報告提供全球膽道癌症治療藥市場相關調查分析,提供主要的開發平台藥物,臨床實驗,法規,專利資訊,10年的盛行率預測,專利·取得交易等系統性資訊。

要點

疾病的背景

治療

  • 手術
  • 放射線治療
  • 化療
  • 緩和療法

流行病學

開發平台藥物

今後預測的事件

專利·資產取得交易

本源專利

臨床實驗形勢

參考文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0184935

This Market Spotlight report covers the Biliary Tract Cancer market, comprising key pipeline drugs, recent events and analyst opinion, clinical trials, upcoming events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.

Key Takeaways:

Datamonitor Healthcare estimates that in 2018, there were approximately 397,700 incident cases of biliary tract cancer (BTC) worldwide, and forecasts that number to increase to 425,600 incident cases by 2027. The majority of industry-sponsored drugs in active clinical development for BTC are in Phase II, with one drug in the NDA/BLA phase.

Therapies in development for BTC focus on a wide variety of targets, with the majority being administered via the oral or intravenous routes.

High-impact upcoming events for drugs in the BTC space comprise topline Phase IIa trial results for Xermelo, an expected PDUFA date for pemigatinib, and topline Phase III trial results for Imfinzi and fimaCHEM.

The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 40.7%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There has been only one licensing and asset acquisition deal involving gallbladder and BTC drugs during 2014-19. The exclusive acquisition agreement signed in 2017 between Mundipharma and CellAct for $250m for the acquisition of CAP7-1 was the only deal.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for biliary tract neoplasms have been in the early and mid-phases of development, with 90% of trials in Phase I-II, and only 10% in Phase III.

The US has a substantial lead in the number of biliary tract neoplasms clinical trials globally. The UK leads the major EU markets, while China and South Korea share the top spot in Asia.

Bristol-Myers Squibb has the highest number of ongoing clinical trials for biliary tract neoplasms, with six trials. AstraZeneca and Bristol-Myers Squibb lead industry sponsors with the highest overall number of clinical trials for biliary tract neoplasms.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Surgery
  • Radiation therapy
  • Chemotherapy
  • Palliative therapy

EPIDEMIOLOGY

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Varlitinib for BTC (November 11, 2019)
  • Tibsovo for BTC (September 30, 2019)
  • Pemigatinib for BTC (September 27, 2019)
  • Tibsovo for BTC (May 15, 2019)
  • Derazantinib for BTC (January 9, 2019)
  • FoundationOne Infigratinib Companion Diagnostic for BTC (June 19, 2018)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of BTC, 2018-27
  • Figure 2: Overview of pipeline drugs for BTC in the US
  • Figure 3: Pipeline drugs for BTC, by company
  • Figure 4: Pipeline drugs for BTC, by drug type
  • Figure 5: Pipeline drugs for BTC, by classification
  • Figure 6: Varlitinib for BTC (November 11, 2019): Phase II/III - TreeTopp
  • Figure 7: Tibsovo for BTC (September 30, 2019): Phase III - ClarIDHy
  • Figure 8: Pemigatinib for BTC (September 27, 2019): Phase II - Cholangiocarcinoma (FIGHT-202)
  • Figure 9: Tibsovo for BTC (May 15, 2019): Phase III - ClarIDHy
  • Figure 10: Derazantinib for BTC (January 9, 2019): Phase II - FIDES-01
  • Figure 11: Key upcoming events in BTC
  • Figure 12: Probability of success in the BTC pipeline
  • Figure 13: Licensing and asset acquisition deals in BTC, 2014-19
  • Figure 14: Parent patents in BTC
  • Figure 15: Clinical trials in BTC
  • Figure 16: Top 10 drugs for clinical trials in BTC
  • Figure 17: Top 10 companies for clinical trials in BTC
  • Figure 18: Trial locations in BTC
  • Figure 19: BTC trials status
  • Figure 20: BTC trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of BTC, 2018-27
  • Table 2: Pipeline drugs for BTC in the US
  • Table 3: Varlitinib for BTC (November 11, 2019)
  • Table 4: Tibsovo for BTC (September 30, 2019)
  • Table 5: Pemigatinib for BTC (September 27, 2019)
  • Table 6: Tibsovo for BTC (May 15, 2019)
  • Table 7: Derazantinib for BTC (January 9, 2019)
  • Table 8: FoundationOne Infigratinib Companion Diagnostic for BTC (June 19, 2018)
Back to Top